

CLAIMS

1. A transdermal preparation containing a muscarinic receptor antagonist and an external preparation base.

5

2. The preparation according to claim 1, wherein the muscarinic receptor antagonist is one or two or more selected from 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide, (+)-  
(R)-2-[ $\alpha$ -[2-(diisopropylamino)ethyl]benzoyl]-p-cresol tartrate,  
10 (S)-1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]- $\alpha,\alpha$ -diphenyl-3-pyrrolidine acetamide hydrobromide, (+)-(1S,3'R)-quinuclidin-3'-yl-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate succinate, 4-diethylamino-2-butynyl ( $\pm$ )- $\alpha$ -cyclohexyl- $\alpha$ -phenylglycolate hydrochloride, 1-methyl-4-piperidyl- $\alpha,\alpha$ -diphenyl- $\alpha$ -n-propoxyacetate hydrochloride, ( $\pm$ )-N-t-butyl-1-methyl-3,3-diphenylpropylamine hydrochloride, and 2-piperidinoethyl-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate.

20 3. The preparation according to claim 2, wherein the muscarinic receptor antagonist is 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide.

4. The preparation according to claim 1 for use as a prophylactic or therapeutic agent for preventing or treating a

disorder in patients with overactive bladder, the disorder selected from increased urinary frequency, urinary incontinence, asthma, chronic airway obstruction, and irritable bowel syndrome.

5

5. The preparation according to claim 4, wherein the disorder is increased urinary frequency and urinary incontinence in patients with overactive bladder.

10 6. The preparation according to claim 1, provided in the form of patch.

7. The preparation according to claim 6, provided in the form of a single adhesive layer-type or a reservoir-type  
15 transdermal preparation.

8. The preparation according to claim 7, containing as an active ingredient a dissolved form of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide alone.

20

9. The preparation according to claim 7, containing as active ingredients dissolved and non-dissolved forms of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide.

25 10. The preparation according to claim 1, wherein the

external preparation base is a base or combination of bases selected from the group consisting of an amphipathic solubilizing agent, a suspension base, a softener, an emulsifier, a buffer, a transdermal permeability enhancer, a 5 tackifier, a tackiness enhancer, an adhesive, a skin irritancy mitigator, and an additive.

11. The transdermal preparation for treating increased urinary frequency and urinary incontinence according to claim 10 1, containing as an active ingredient 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide and comprising an external preparation base and a structural body.

12. The transdermal preparation for treating increased urinary frequency and urinary incontinence according to claim 15 11, which is of a single adhesive layer type, comprising: an adhesive layer formed of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide in conjunction with a single or combination of the external preparation bases; and 20 a structural body comprising a support and a peelable liner.

13. The transdermal preparation for treating increased urinary frequency and urinary incontinence according to claim 25 11, which is of a reservoir type, comprising:

a mixture of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide and a single or combination of the external preparation bases; and

5 a structural body comprising a membrane for controlling drug permeation, an adhesive layer, a support, and a peelable liner.

14. The transdermal preparation for treating increased urinary frequency and urinary incontinence according to any 10 one of claims 11 to 13, wherein the external preparation base comprises a compound or combination of compounds selected from the group consisting of a water-soluble polymer, a fat-soluble polymer, a fatty acid, a fatty acid ester, a fatty acid metal salt, animal or plant fats and oils, an alcohol, a terpene 15 compound, and water.